Brief: Tonix Pharmaceuticals Announces Issuance Of U.S. Patent For FDA-Approved Tosymra® To Treat Migraines
19/09/2024 12:38
Sept 19 (Reuters) - Tonix Pharmaceuticals Holding Corp
TNXP.O :
* TONIX PHARMACEUTICALS ANNOUNCES ISSUANCE OF U.S. PATENT BY
THE
UNITED STATES PATENT AND TRADEMARK OFFICE COVERING THE
INTRANASAL DELIVERY OF FDA-APPROVED TOSYMRA® TO TREAT MIGRAINES
* TONIX PHARMACEUTICALS HOLDING CORP: NEW PATENT EXPECTED
TO
EXPIRE IN 2030
Source text for Eikon: ID:nGNX99tZqb
Further company coverage: TNXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview